Q15109
PR
Gene name |
AGER (RAGE) |
Protein name |
Advanced glycosylation end product-specific receptor |
Names |
Receptor for advanced glycosylation end products |
Species |
Homo sapiens (Human) |
KEGG Pathway |
hsa:177 |
EC number |
|
Protein Class |
|
Descriptions
The autoinhibited protein was predicted that may have potential autoinhibitory elements via cis-regPred.
Autoinhibitory domains (AIDs)
Target domain |
|
Relief mechanism |
|
Assay |
cis-regPred |
Accessory elements
No accessory elements
Autoinhibited structure
Activated structure
32 structures for Q15109
| Entry ID | Method | Resolution | Chain | Position | Source |
|---|---|---|---|---|---|
| 2E5E | NMR | - | A | 23-121 | PDB |
| 2ENS | NMR | - | A | 235-323 | PDB |
| 2L7U | NMR | - | A | 23-125 | PDB |
| 2LE9 | NMR | - | A/D | 235-327 | PDB |
| 2LMB | NMR | - | A | 363-404 | PDB |
| 2M1K | NMR | - | A/C | 23-121 | PDB |
| 2MJW | NMR | - | A/C | 23-121 | PDB |
| 2MOV | NMR | - | A | 23-125 | PDB |
| 3CJJ | X-ray | 185 A | A | 23-240 | PDB |
| 3O3U | X-ray | 150 A | N | 23-231 | PDB |
| 4LP4 | X-ray | 240 A | A/B | 23-231 | PDB |
| 4LP5 | X-ray | 380 A | A/B | 23-323 | PDB |
| 4OF5 | X-ray | 280 A | A/B | 23-237 | PDB |
| 4OFV | X-ray | 310 A | A/B | 23-235 | PDB |
| 4OI7 | X-ray | 310 A | A/B | 23-237 | PDB |
| 4OI8 | X-ray | 310 A | A/B | 23-237 | PDB |
| 4P2Y | X-ray | 230 A | A | 23-323 | PDB |
| 4XYN | X-ray | 255 A | P | 54-68 | PDB |
| 4YBH | X-ray | 240 A | A | 23-323 | PDB |
| 5D7F | X-ray | 130 A | P | 65-79 | PDB |
| 6VXG | NMR | - | A | 362-404 | PDB |
| 6XQ1 | X-ray | 151 A | A/B | 23-231 | PDB |
| 6XQ3 | X-ray | 171 A | A/B | 23-231 | PDB |
| 6XQ5 | X-ray | 180 A | A/B | 23-231 | PDB |
| 6XQ6 | X-ray | 190 A | A/B | 23-231 | PDB |
| 6XQ7 | X-ray | 180 A | A/B | 23-231 | PDB |
| 6XQ8 | X-ray | 182 A | A/B | 23-231 | PDB |
| 6XQ9 | X-ray | 230 A | A/B | 23-231 | PDB |
| 7LML | X-ray | 215 A | A/B | 23-231 | PDB |
| 7LMW | X-ray | 250 A | A/B | 23-231 | PDB |
| 8I9M | EM | 519 A | B | 23-233 | PDB |
| AF-Q15109-F1 | Predicted | AlphaFoldDB |
355 variants for Q15109
| Variant ID(s) | Position | Change | Description | Diseaes Association | Provenance |
|---|---|---|---|---|---|
|
rs1303246578 CA363521974 |
3 | A>S | No |
gnomAD ClinGen |
|
| TCGA novel | 4 | G>E | Variant assessed as Somatic; impact. [NCI-TCGA] | No | NCI-TCGA |
|
rs769151684 CA3738347 |
4 | G>R | No |
ExAC TOPMed gnomAD ClinGen |
|
|
CA363521954 rs1582726095 |
4 | G>V | No |
Ensembl ClinGen |
|
|
rs749621938 CA3738346 |
5 | T>I | No |
ExAC TOPMed gnomAD ClinGen |
|
|
rs780466274 CA3738345 |
6 | A>V | No |
ExAC TOPMed gnomAD ClinGen |
|
|
CA363521927 rs1429110720 |
7 | V>F | No |
TOPMed ClinGen |
|
|
rs1582725950 CA363521910 |
8 | G>A | No |
Ensembl ClinGen |
|
|
rs770047253 CA3738344 |
11 | V>M | Variant assessed as Somatic; 0.0 impact. [NCI-TCGA] | No |
ClinGen ExAC NCI-TCGA gnomAD |
|
rs746054660 CA3738343 |
12 | L>M | No |
ExAC gnomAD ClinGen |
|
|
rs781349075 CA3738342 |
13 | V>I | No |
ClinGen ExAC TOPMed gnomAD |
|
| TCGA novel | 15 | S>G | Variant assessed as Somatic; impact. [NCI-TCGA] | No | NCI-TCGA |
|
rs1490219403 CA363521795 |
17 | W>* | No |
gnomAD ClinGen |
|
| rs372263884 | 18 | G>= | Variant assessed as Somatic; 0.0 impact. [NCI-TCGA] | No | NCI-TCGA |
|
rs1462518063 CA363521733 |
18 | G>E | No |
ClinGen gnomAD |
|
| TCGA novel | 18 | G>R | Variant assessed as Somatic; impact. [NCI-TCGA] | No | NCI-TCGA |
|
CA3738325 rs781404248 |
19 | A>G | No |
ClinGen ExAC gnomAD |
|
|
CA363521719 rs1351809323 |
20 | V>I | No |
TOPMed ClinGen |
|
|
CA363521699 rs1320964562 |
21 | V>A | No |
gnomAD ClinGen |
|
|
CA363521652 rs1279543943 |
25 | N>Y | No |
gnomAD ClinGen |
|
|
CA363521617 rs1437325653 |
27 | T>I | No |
TOPMed ClinGen |
|
|
CA363521611 rs771072935 |
28 | A>S | No |
ExAC gnomAD ClinGen |
|
|
CA3738324 rs771072935 |
28 | A>T | No |
ClinGen ExAC gnomAD |
|
|
rs17846804 CA3738323 |
28 | A>V | No |
1000Genomes ExAC TOPMed gnomAD ClinGen |
|
|
rs144337279 CA363521604 |
29 | R>G | No |
ESP ExAC TOPMed gnomAD ClinGen |
|
|
rs754920335 CA3738321 |
29 | R>Q | No |
ExAC TOPMed gnomAD ClinGen |
|
|
rs144337279 CA3738322 |
29 | R>W | No |
ESP ExAC TOPMed gnomAD ClinGen |
|
|
rs753777863 CA3738320 |
30 | I>M | No |
ExAC gnomAD ClinGen |
|
|
rs971829597 CA136917856 |
30 | I>T | No |
Ensembl ClinGen |
|
|
rs1034066092 CA136917880 |
30 | I>V | No |
ClinGen TOPMed gnomAD |
|
|
CA3738318 rs780101221 |
31 | G>D | No |
ExAC gnomAD ClinGen |
|
|
CA136917833 rs983388476 |
32 | E>K | No |
Ensembl ClinGen |
|
|
rs199964705 CA3738315 |
33 | P>L | No |
1000Genomes ExAC TOPMed gnomAD ClinGen |
|
|
rs751092386 CA3738313 |
37 | K>N | No |
ExAC gnomAD ClinGen |
|
|
CA3738312 rs201829223 |
38 | C>W | No |
ExAC TOPMed gnomAD ClinGen |
|
|
CA136917823 rs950976609 |
38 | C>Y | No |
Ensembl ClinGen |
|
|
CA3738311 rs762326598 |
40 | G>R | No |
ExAC TOPMed gnomAD ClinGen |
|
|
CA363521414 rs1376275470 |
44 | K>E | No |
gnomAD ClinGen |
|
|
CA363521383 rs1381450072 |
46 | P>H | No |
TOPMed ClinGen |
|
|
CA363521388 rs1226933150 |
46 | P>S | No |
TOPMed gnomAD ClinGen |
|
|
rs35030981 CA3738304 |
48 | R>Q | No |
ESP ExAC TOPMed gnomAD ClinGen |
|
|
rs375902201 CA3738305 |
48 | R>W | No |
ESP ExAC TOPMed gnomAD ClinGen |
|
|
CA363521340 rs1392156413 |
50 | E>K | No |
ClinGen gnomAD |
|
|
rs35802968 CA3738302 |
51 | W>* | No |
1000Genomes ESP ExAC TOPMed gnomAD ClinGen |
|
|
rs1004567640 CA136917786 |
51 | W>G | No |
TOPMed gnomAD ClinGen |
|
|
rs890847537 CA136916324 |
54 | N>S | No |
TOPMed ClinGen |
|
|
rs1029338786 CA136916311 |
56 | G>A | No |
Ensembl ClinGen |
|
|
rs1361657410 CA363519865 |
56 | G>S | No |
gnomAD ClinGen |
|
|
rs766743440 CA3738286 |
57 | R>G | No |
ExAC TOPMed gnomAD ClinGen |
|
|
CA3738284 rs760899334 |
57 | R>Q | No |
ExAC TOPMed gnomAD ClinGen |
|
|
rs766743440 CA3738285 |
57 | R>W | No |
ExAC TOPMed gnomAD ClinGen |
|
|
rs1267532993 CA363519816 |
58 | T>I | No |
gnomAD ClinGen |
|
|
rs1450389456 CA363519765 |
61 | W>* | No |
gnomAD ClinGen |
|
|
rs748270365 CA3738280 |
63 | V>G | No |
ClinGen ExAC gnomAD |
|
|
CA3738281 rs772117797 |
63 | V>I | No |
ClinGen ExAC gnomAD |
|
|
rs1225544408 CA363519666 |
65 | S>Y | No |
gnomAD ClinGen |
|
|
CA363519614 rs1282723686 |
69 | G>R | No |
ClinGen gnomAD |
|
|
CA3738278 rs769914792 |
70 | G>S | No |
ExAC TOPMed gnomAD ClinGen |
|
|
rs200718197 CA136916269 |
72 | W>* | No |
TOPMed ClinGen |
|
|
rs781231923 CA3738276 |
73 | D>N | No |
ExAC gnomAD ClinGen |
|
|
CA3738275 rs757110799 |
74 | S>G | No |
ExAC TOPMed gnomAD ClinGen |
|
|
CA363519532 rs1382474149 |
74 | S>N | No |
gnomAD ClinGen |
|
|
rs1178205910 CA363519494 |
76 | A>V | No |
gnomAD ClinGen |
|
|
RCV000952525 rs80096349 CA3738273 |
77 | R>C | No |
1000Genomes ESP ExAC TOPMed gnomAD ClinGen ClinVar dbSNP |
|
|
CA3738272 rs752272002 |
77 | R>H | No |
ExAC TOPMed gnomAD ClinGen |
|
|
rs752272002 CA3738271 |
77 | R>L | No |
ClinGen ExAC TOPMed gnomAD |
|
|
CA3738270 rs752272002 |
77 | R>P | No |
ExAC TOPMed gnomAD ClinGen |
|
|
CA363519457 rs1402786409 |
79 | L>F | No |
TOPMed ClinGen |
|
|
rs755528021 CA3738268 |
79 | L>R | No |
ExAC gnomAD ClinGen |
|
|
CA3738266 rs766755123 |
81 | N>H | No |
ExAC gnomAD ClinGen |
|
|
rs1044599245 CA136916200 |
81 | N>S | No |
TOPMed gnomAD ClinGen |
|
| rs2070600 | 82 | G>G | No |
1000Genomes ESP ExAC TOPMed gnomAD |
|
|
VAR_024500 CA3738264 rs2070600 |
82 | G>S | No |
1000Genomes ESP ExAC TOPMed gnomAD ClinGen UniProt dbSNP |
|
|
rs767835218 CA3738263 |
84 | L>P | No |
ExAC gnomAD ClinGen |
|
|
rs767835218 CA136916181 |
84 | L>R | No |
ExAC gnomAD ClinGen |
|
|
CA136916185 rs983419885 |
84 | L>V | No |
Ensembl ClinGen |
|
|
CA136916177 rs920874056 |
85 | F>S | No |
ClinGen TOPMed |
|
|
rs762118793 CA3738262 |
86 | L>F | No |
ExAC TOPMed gnomAD ClinGen |
|
|
CA3738261 rs774609967 |
87 | P>L | No |
ExAC TOPMed gnomAD ClinGen |
|
|
rs1429914100 CA363519340 |
88 | A>T | No |
gnomAD ClinGen |
|
|
CA363519326 rs1258326838 |
89 | V>I | No |
TOPMed ClinGen |
|
|
CA3738257 rs770719664 |
90 | G>R | Variant assessed as Somatic; 0.0 impact. [NCI-TCGA] | No |
ExAC TOPMed gnomAD ClinGen NCI-TCGA |
|
CA363519265 rs1194729041 |
93 | D>N | No |
ClinGen TOPMed |
|
|
rs1469997690 CA363519241 |
94 | E>D | No |
ClinGen gnomAD |
|
|
CA136916140 rs955109132 |
95 | G>A | No |
Ensembl ClinGen |
|
|
CA363519182 rs777428643 |
98 | R>P | No |
ExAC TOPMed gnomAD ClinGen |
|
|
CA3738255 rs777428643 |
98 | R>Q | Variant assessed as Somatic; 4.622e-05 impact. [NCI-TCGA] | No |
ExAC TOPMed gnomAD ClinGen NCI-TCGA |
|
rs1419563792 CA363519164 |
99 | C>W | No |
gnomAD ClinGen |
|
|
rs1475364918 CA363519149 |
100 | Q>H | No |
gnomAD ClinGen |
|
|
rs771797821 CA3738254 |
100 | Q>L | No |
ExAC TOPMed gnomAD ClinGen |
|
| VAR_011338 | 100 | Q>R | No | UniProt | |
|
CA363519138 rs747777558 |
101 | A>E | No |
ExAC gnomAD ClinGen |
|
|
rs1582719739 CA363519144 |
101 | A>T | No |
Ensembl ClinGen |
|
|
CA3738253 rs747777558 |
101 | A>V | No |
ExAC gnomAD ClinGen |
|
|
rs1329601620 CA363519121 |
102 | M>T | No |
gnomAD ClinGen |
|
|
rs1038867772 CA136916108 |
103 | N>S | No |
TOPMed ClinGen |
|
|
CA3738252 rs778489029 |
104 | R>K | No |
ExAC gnomAD ClinGen |
|
|
rs778489029 CA136916107 |
104 | R>M | No |
ExAC gnomAD ClinGen |
|
|
rs754514021 CA3738251 |
107 | K>R | No |
ExAC gnomAD ClinGen |
|
|
rs753277480 CA3738250 |
108 | E>K | No |
ExAC gnomAD ClinGen |
|
|
rs753277480 CA363519012 |
108 | E>Q | No |
ExAC gnomAD ClinGen |
|
|
rs147376814 CA136916086 |
110 | K>R | No |
ESP TOPMed gnomAD ClinGen |
|
|
CA136916074 rs1033368340 |
112 | N>K | No |
Ensembl ClinGen |
|
|
rs1213984720 CA363518903 |
113 | Y>C | No |
gnomAD ClinGen |
|
|
rs373195347 CA3738248 |
114 | R>* | No |
ESP ExAC TOPMed gnomAD ClinGen |
|
|
COSM1443583 rs17846806 CA3738247 |
114 | R>Q | Variant assessed as Somatic; 0.0 impact. large_intestine [NCI-TCGA, Cosmic] | No |
ExAC TOPMed gnomAD ClinGen cosmic curated NCI-TCGA |
|
CA3738246 rs767739122 |
115 | V>A | No |
ClinGen ExAC gnomAD |
|
|
rs1453036075 CA363518869 |
115 | V>I | No |
gnomAD ClinGen |
|
|
rs762171687 CA3738245 |
116 | R>C | No |
ExAC gnomAD ClinGen |
|
|
CA3738244 rs764348350 |
116 | R>H | No |
ExAC TOPMed gnomAD ClinGen |
|
|
CA3738243 rs764348350 |
116 | R>L | No |
ExAC TOPMed gnomAD ClinGen |
|
|
CA136916051 rs142731923 |
119 | Q>* | No |
ESP TOPMed ClinGen |
|
|
CA363518281 rs1181586858 |
120 | I>T | No |
ClinGen gnomAD |
|
|
rs764471105 CA3738223 |
121 | P>L | No |
ExAC gnomAD ClinGen |
|
|
rs1236437480 CA363518267 |
121 | P>S | No |
gnomAD ClinGen |
|
|
CA3738222 rs758692000 |
122 | G>V | No |
ClinGen ExAC gnomAD |
|
|
CA3738221 rs752864070 |
123 | K>E | No |
ExAC gnomAD ClinGen |
|
|
CA363518219 rs1490164394 |
124 | P>S | No |
gnomAD ClinGen |
|
|
CA3738220 rs765211637 |
125 | E>* | No |
ExAC gnomAD ClinGen |
|
|
CA363518205 rs765211637 |
125 | E>K | No |
ExAC gnomAD ClinGen |
|
|
CA3738219 rs759612451 |
125 | E>V | No |
ExAC gnomAD ClinGen |
|
|
CA3738217 rs767375903 |
127 | V>G | No |
ExAC gnomAD ClinGen |
|
|
rs773054732 CA363518166 |
127 | V>I | No |
ExAC TOPMed gnomAD ClinGen |
|
|
rs773054732 CA3738218 |
127 | V>L | No |
ExAC TOPMed gnomAD ClinGen |
|
|
rs1346913561 CA363518126 |
129 | S>P | No |
TOPMed gnomAD ClinGen |
|
|
rs1406097485 CA363518042 |
133 | L>F | No |
ClinGen gnomAD |
|
| TCGA novel | 134 | T>K | Variant assessed as Somatic; impact. [NCI-TCGA] | No | NCI-TCGA |
|
rs774118475 CA3738215 |
134 | T>M | No |
ExAC TOPMed ClinGen |
|
|
CA136915719 rs970004346 |
135 | A>V | No |
gnomAD ClinGen |
|
|
CA3738212 rs748857863 |
137 | V>F | No |
ExAC gnomAD ClinGen |
|
|
CA363517935 rs1346121969 |
139 | N>S | No |
gnomAD ClinGen |
|
|
rs372397484 CA363517484 CA363517479 |
141 | V>L | No |
ESP ExAC TOPMed gnomAD ClinGen |
|
|
rs372397484 CA3738187 |
141 | V>M | No |
ESP ExAC TOPMed gnomAD ClinGen |
|
|
CA363517450 rs1462448081 |
143 | T>A | No |
gnomAD ClinGen |
|
|
CA3738185 rs747497137 |
144 | C>R | No |
ExAC gnomAD ClinGen |
|
|
CA3738184 rs138726985 |
144 | C>W | No |
1000Genomes ESP ExAC TOPMed gnomAD ClinGen |
|
|
rs1385606672 CA363517408 |
145 | V>E | No |
gnomAD ClinGen |
|
|
rs938707778 CA136915419 |
146 | S>L | No |
TOPMed ClinGen |
|
|
rs1582715341 CA363517374 |
148 | G>R | No |
Ensembl ClinGen |
|
| TCGA novel | 149 | S>N | Variant assessed as Somatic; impact. [NCI-TCGA] | No | NCI-TCGA |
|
CA363517325 rs1561877886 |
150 | Y>* | No |
Ensembl ClinGen |
|
|
rs758721461 CA3738183 |
151 | P>L | No |
ExAC gnomAD ClinGen |
|
|
rs368175894 CA136915401 |
152 | A>T | No |
ESP ClinGen |
|
|
CA3738181 rs779015120 |
157 | W>* | No |
ExAC TOPMed gnomAD ClinGen |
|
|
CA3738180 rs188057660 |
159 | L>F | No |
1000Genomes ExAC TOPMed gnomAD ClinGen |
|
|
rs1340132310 CA363517119 |
159 | L>V | No |
TOPMed ClinGen |
|
|
rs753930486 CA3738179 |
161 | G>W | No |
ExAC gnomAD ClinGen |
|
|
rs1280330660 CA363517011 |
163 | P>L | No |
TOPMed ClinGen |
|
|
rs780075796 CA3738178 |
164 | L>V | No |
ExAC TOPMed gnomAD ClinGen |
|
|
rs757232464 CA3738177 |
167 | N>K | No |
ExAC TOPMed gnomAD ClinGen |
|
|
rs1316165489 CA363516843 |
170 | G>R | No |
gnomAD ClinGen |
|
|
rs756213091 CA3738159 |
171 | V>L | No |
ExAC gnomAD ClinGen |
|
|
rs750431822 CA3738158 |
172 | S>P | No |
ExAC TOPMed gnomAD ClinGen |
|
|
CA3738156 rs758356148 |
177 | T>I | No |
ExAC gnomAD ClinGen |
|
|
rs1406700508 CA363516518 |
178 | R>K | No |
gnomAD ClinGen |
|
|
CA3738155 rs752477230 |
178 | R>S | No |
ExAC TOPMed gnomAD ClinGen |
|
|
CA136915261 rs370118672 |
179 | R>G | No |
ESP TOPMed gnomAD ClinGen |
|
|
CA363516476 rs1369648421 |
180 | H>Y | No |
TOPMed ClinGen |
|
|
CA363516465 rs1308432510 |
181 | P>A | No |
TOPMed ClinGen |
|
|
rs1386843555 CA363516439 |
182 | E>D | No |
gnomAD ClinGen |
|
|
rs765062897 CA3738154 |
182 | E>K | No |
ClinGen ExAC gnomAD |
|
|
CA3738153 rs759204120 |
187 | T>S | No |
ExAC TOPMed gnomAD ClinGen |
|
|
rs1242015912 CA363516327 |
189 | Q>P | No |
TOPMed ClinGen |
|
|
rs766063160 CA3738152 |
190 | S>* | No |
ExAC TOPMed gnomAD ClinGen |
|
|
CA3738151 rs766063160 |
190 | S>L | Variant assessed as Somatic; 0.0 impact. [NCI-TCGA] | No |
ExAC TOPMed gnomAD ClinGen NCI-TCGA |
|
rs772521595 CA3738148 |
191 | E>K | No |
ExAC gnomAD ClinGen |
|
|
rs1247762563 CA363516234 |
193 | M>T | No |
gnomAD ClinGen |
|
| TCGA novel | 193 | M>V | Variant assessed as Somatic; impact. [NCI-TCGA] | No | NCI-TCGA |
|
rs762348263 CA3738147 |
194 | V>L | No |
ExAC TOPMed gnomAD ClinGen |
|
|
CA363516125 rs1247878317 |
195 | T>I | No |
TOPMed ClinGen |
|
|
CA363516091 rs1450290619 |
197 | A>P | No |
gnomAD ClinGen |
|
|
rs375056984 CA3738144 |
198 | R>Q | No |
ExAC TOPMed gnomAD ClinGen |
|
|
rs368048335 CA3738145 |
198 | R>W | No |
ESP ExAC TOPMed gnomAD ClinGen |
|
|
CA363516037 rs1328669957 |
199 | G>E | No |
gnomAD ClinGen |
|
|
rs1266328695 CA363516004 |
201 | D>N | Variant assessed as Somatic; 0.0 impact. [NCI-TCGA] | No |
gnomAD ClinGen NCI-TCGA |
|
rs1368252277 CA363515970 |
202 | P>S | Variant assessed as Somatic; 0.0 impact. [NCI-TCGA] | No |
TOPMed gnomAD ClinGen NCI-TCGA |
|
rs780256052 CA3738143 |
203 | R>C | No |
ExAC gnomAD ClinGen |
|
|
CA3738142 rs769993380 |
203 | R>H | No |
ExAC TOPMed gnomAD ClinGen |
|
|
rs373910069 CA3738141 |
206 | F>S | No |
1000Genomes ESP ExAC TOPMed gnomAD ClinGen |
|
|
rs1433926283 CA363515876 |
207 | S>F | No |
gnomAD ClinGen |
|
|
rs781303691 CA3738140 |
207 | S>P | No |
ExAC gnomAD ClinGen |
|
|
CA363515865 rs1404919101 |
208 | C>R | No |
TOPMed ClinGen |
|
|
rs1368198317 CA363515858 |
208 | C>Y | No |
TOPMed gnomAD ClinGen |
|
|
rs1178009793 CA363515755 |
211 | S>R | No |
ClinGen gnomAD |
|
|
CA363515749 rs1469908411 |
212 | P>S | No |
gnomAD ClinGen |
|
|
rs767497303 COSM1546181 CA136915178 |
213 | G>V | lung [Cosmic] | No |
Ensembl ClinGen cosmic curated |
|
CA363515652 rs1244194657 |
215 | P>R | No |
TOPMed gnomAD ClinGen |
|
|
rs562985782 CA3738136 |
215 | P>S | No |
1000Genomes ExAC TOPMed gnomAD ClinGen |
|
|
CA3738135 rs202226593 |
216 | R>* | No |
ExAC TOPMed gnomAD ClinGen |
|
|
CA3738134 rs202226593 |
216 | R>G | No |
ExAC TOPMed gnomAD ClinGen |
|
|
CA363515627 rs1246376753 |
216 | R>Q | No |
gnomAD ClinGen |
|
|
rs1205772220 CA363515609 |
217 | H>R | No |
ClinGen gnomAD |
|
|
rs766191033 CA3738131 |
218 | R>Q | No |
ClinGen ExAC TOPMed gnomAD |
|
|
CA3738132 rs149408505 |
218 | R>W | No |
ExAC TOPMed gnomAD ClinGen |
|
|
CA136915142 rs905897540 |
219 | A>P | No |
TOPMed ClinGen |
|
|
rs755823726 CA3738130 |
220 | L>F | No |
ExAC gnomAD ClinGen |
|
|
rs749990828 CA3738129 |
221 | R>C | No |
ExAC gnomAD ClinGen |
|
|
rs1434042548 CA363515521 |
221 | R>H | No |
gnomAD ClinGen |
|
|
rs1362733488 CA363515485 |
223 | A>S | No |
gnomAD ClinGen |
|
|
rs1338356284 CA363515453 |
224 | P>H | No |
TOPMed gnomAD ClinGen |
|
|
rs767029626 CA3738128 |
225 | I>L | No |
ExAC gnomAD ClinGen |
|
|
CA3738127 rs761176006 |
226 | Q>* | No |
ExAC TOPMed gnomAD ClinGen |
|
|
CA363515405 rs1197423769 |
226 | Q>R | No |
TOPMed ClinGen |
|
| TCGA novel | 227 | P>A | Variant assessed as Somatic; impact. [NCI-TCGA] | No | NCI-TCGA |
|
CA3738126 rs774950609 |
227 | P>L | No |
ExAC TOPMed gnomAD ClinGen |
|
|
CA3738125 rs764437307 |
228 | R>C | No |
ExAC gnomAD ClinGen |
|
|
rs763317920 CA3738124 |
228 | R>H | No |
ExAC TOPMed gnomAD ClinGen |
|
|
rs754344673 CA136915103 |
229 | V>I | No |
Ensembl ClinGen |
|
|
CA3738123 rs775831505 |
230 | W>C | No |
ExAC TOPMed ClinGen |
|
|
rs746070734 CA3738120 |
231 | E>* | No |
ExAC gnomAD ClinGen |
|
|
CA363515089 rs539453209 CA3738096 |
231 | E>D | No |
ExAC TOPMed gnomAD ClinGen |
|
|
rs746070734 CA3738121 |
231 | E>K | No |
ExAC gnomAD ClinGen |
|
|
rs1366680556 CA363515076 |
232 | P>S | Variant assessed as Somatic; impact. [NCI-TCGA] | No |
gnomAD ClinGen NCI-TCGA |
|
CA363515052 rs1409763628 |
233 | V>E | No |
ClinGen TOPMed gnomAD |
|
|
CA363515032 rs1349122196 |
234 | P>L | No |
gnomAD ClinGen |
|
|
CA363514993 rs1295688607 |
237 | E>K | No |
ClinGen gnomAD |
|
|
CA3738095 rs780090863 |
238 | V>F | No |
ExAC TOPMed gnomAD ClinGen |
|
|
rs992416658 CA136914927 |
239 | Q>* | No |
ClinGen Ensembl |
|
|
CA363514938 rs1349644380 |
239 | Q>P | No |
gnomAD ClinGen |
|
|
rs17846799 CA3738093 |
241 | V>L | No |
ExAC TOPMed gnomAD ClinGen |
|
|
CA3738092 rs780907936 |
242 | V>M | No |
ExAC TOPMed gnomAD ClinGen |
|
|
rs751124444 CA3738090 |
243 | E>A | No |
ExAC gnomAD ClinGen |
|
|
CA3738089 rs777245704 |
244 | P>Q | No |
ExAC gnomAD ClinGen |
|
|
CA363514817 rs1401530406 |
245 | E>K | No |
TOPMed gnomAD ClinGen |
|
|
rs150282885 CA3738087 |
246 | G>D | No |
ESP ExAC TOPMed gnomAD ClinGen |
|
|
rs757859815 CA3738088 |
246 | G>S | No |
ExAC gnomAD ClinGen |
|
|
CA3738086 rs765667409 |
247 | G>E | No |
ExAC gnomAD ClinGen |
|
|
CA3738085 rs376859625 |
248 | A>G | No |
ESP ExAC TOPMed gnomAD ClinGen |
|
|
CA363514730 rs376859625 |
248 | A>V | No |
ESP ExAC TOPMed gnomAD ClinGen |
|
|
CA363514711 rs1466119818 |
249 | V>A | No |
ClinGen gnomAD |
|
|
rs754141936 CA3738083 |
250 | A>G | No |
ExAC TOPMed gnomAD ClinGen |
|
|
rs759673885 CA136914839 |
250 | A>T | No |
Ensembl ClinGen |
|
|
rs766692052 CA3738082 |
252 | G>S | No |
ExAC TOPMed gnomAD ClinGen |
|
|
rs772300820 CA3738078 |
255 | V>I | No |
ExAC TOPMed gnomAD ClinGen |
|
|
CA363514559 rs1216234933 |
256 | T>A | No |
TOPMed ClinGen |
|
|
rs775569298 CA3738076 |
259 | C>F | No |
ExAC TOPMed gnomAD ClinGen |
|
|
rs775569298 CA3738077 |
259 | C>Y | No |
ExAC TOPMed gnomAD ClinGen |
|
|
CA3738075 rs201178949 |
261 | V>D | No |
ExAC TOPMed gnomAD ClinGen |
|
|
rs745731408 CA3738074 |
262 | P>R | No |
ClinGen ExAC gnomAD |
|
|
CA3738073 rs780821490 |
264 | Q>* | No |
ExAC gnomAD ClinGen |
|
|
rs1176777162 CA363514314 |
267 | P>S | No |
gnomAD ClinGen |
|
| TCGA novel | 267 | P>S | Variant assessed as Somatic; impact. [NCI-TCGA] | No | NCI-TCGA |
|
RCV000881806 CA3738072 rs140930365 COSM328183 |
271 | W>R | pancreas [Cosmic] | No |
1000Genomes ESP ExAC TOPMed gnomAD ClinGen cosmic curated ClinVar dbSNP |
|
CA363514196 rs1265018001 |
271 | W>S | No |
gnomAD ClinGen |
|
|
CA3738069 rs777368483 |
274 | D>E | No |
ExAC gnomAD ClinGen |
|
|
rs746666846 CA3738070 |
274 | D>N | No |
ExAC gnomAD ClinGen |
|
|
rs751726848 CA3738039 |
275 | G>D | Variant assessed as Somatic; 0.0 impact. [NCI-TCGA] | No |
ExAC gnomAD ClinGen NCI-TCGA |
|
CA3738038 rs764105620 |
276 | V>M | No |
ExAC TOPMed gnomAD ClinGen |
|
| TCGA novel | 277 | P>C | Variant assessed as Somatic; impact. [NCI-TCGA] | No | NCI-TCGA |
|
CA363513684 rs1473585151 |
279 | P>S | No |
TOPMed gnomAD ClinGen |
|
|
CA136914517 rs566837079 |
281 | P>L | No |
1000Genomes ClinGen |
|
|
rs763052062 CA3738036 |
281 | P>S | No |
ExAC ClinGen |
|
| TCGA novel | 283 | S>A | Variant assessed as Somatic; impact. [NCI-TCGA] | No | NCI-TCGA |
| TCGA novel | 283 | S>L | Variant assessed as Somatic; impact. [NCI-TCGA] | No | NCI-TCGA |
|
CA363513564 rs1465501937 |
284 | P>H | No |
TOPMed ClinGen |
|
|
CA3738034 rs776441058 |
284 | P>S | No |
ExAC gnomAD ClinGen |
|
|
CA3738032 rs766283267 |
286 | L>V | No |
ExAC TOPMed gnomAD ClinGen |
|
|
CA363513492 rs1392301279 |
288 | L>F | No |
TOPMed ClinGen |
|
|
CA136914445 rs948481571 |
289 | P>R | No |
TOPMed gnomAD ClinGen |
|
|
rs201866140 CA3738030 |
290 | E>Q | No |
ESP ExAC TOPMed gnomAD ClinGen |
|
|
CA363513409 rs1194395987 |
291 | I>T | No |
gnomAD ClinGen |
|
|
CA3738029 rs771753637 |
292 | G>R | No |
ExAC gnomAD ClinGen |
|
|
CA3738027 rs201967398 |
293 | P>L | No |
1000Genomes ExAC TOPMed gnomAD ClinGen |
|
|
rs747775472 CA3738028 |
293 | P>S | No |
ExAC gnomAD ClinGen |
|
|
rs768082872 CA363513351 |
294 | Q>* | No |
ExAC gnomAD ClinGen |
|
|
rs768082872 CA3738026 |
294 | Q>E | No |
ExAC gnomAD ClinGen |
|
|
CA363513347 rs1561872833 |
294 | Q>R | No |
Ensembl ClinGen |
|
|
CA363513327 rs1317366314 |
295 | D>G | No |
TOPMed ClinGen |
|
|
rs748764768 CA3738024 |
298 | T>A | No |
ExAC gnomAD ClinGen |
|
|
rs992491898 CA136914401 |
299 | Y>* | No |
TOPMed gnomAD ClinGen |
|
|
rs1196731729 CA363513293 |
299 | Y>S | No |
TOPMed ClinGen |
|
|
CA3738022 RCV000881805 COSM328182 rs138178120 |
301 | C>S | pancreas [Cosmic] | No |
1000Genomes ESP ExAC TOPMed gnomAD ClinGen cosmic curated ClinVar dbSNP |
|
CA3738023 rs138178120 |
301 | C>Y | No |
ClinGen 1000Genomes ESP ExAC TOPMed gnomAD |
|
|
CA363513274 rs1406915297 |
302 | V>M | No |
gnomAD ClinGen |
|
|
rs919204442 CA136914385 |
303 | A>D | No |
Ensembl ClinGen |
|
|
CA363513220 rs1391153880 |
305 | H>R | No |
gnomAD ClinGen |
|
|
CA3738020 rs781659987 |
308 | H>P | No |
ClinGen ExAC TOPMed gnomAD |
|
|
rs751865269 CA3738019 |
308 | H>Q | No |
ExAC TOPMed gnomAD ClinGen |
|
|
CA3738017 rs138186526 CA3738016 |
309 | G>R | No |
1000Genomes ESP ExAC TOPMed gnomAD ClinGen |
|
|
CA3738015 rs752810622 |
311 | Q>R | No |
ClinGen ExAC |
|
|
CA3738014 rs766294601 |
314 | R>C | No |
ExAC gnomAD ClinGen |
|
|
CA3738013 RCV000966990 rs77170610 |
314 | R>H | No |
1000Genomes ESP ExAC TOPMed gnomAD ClinGen ClinVar dbSNP |
|
|
CA363513013 rs1453748410 |
316 | V>I | No |
ClinGen gnomAD |
|
|
CA3738012 rs529074355 |
317 | S>G | No |
1000Genomes ExAC TOPMed gnomAD ClinGen |
|
|
rs1209475983 CA363512988 |
317 | S>N | No |
gnomAD ClinGen |
|
|
rs1209475983 CA363512986 |
317 | S>T | No |
gnomAD ClinGen |
|
|
CA363512940 rs1332885836 |
319 | S>I | No |
gnomAD ClinGen |
|
|
rs767320838 CA363512903 |
321 | I>M | No |
ExAC TOPMed gnomAD ClinGen |
|
|
CA3738009 rs761554882 |
322 | E>K | No |
ExAC TOPMed gnomAD ClinGen |
|
|
rs1295731702 CA363511037 |
323 | P>S | No |
TOPMed ClinGen |
|
| TCGA novel | 324 | G>V | Variant assessed as Somatic; impact. [NCI-TCGA] | No | NCI-TCGA |
|
rs552065901 CA136913837 |
325 | E>K | No |
ClinGen 1000Genomes TOPMed gnomAD |
|
|
CA363510984 rs1473552449 |
326 | E>A | No |
gnomAD ClinGen |
|
|
rs1271261448 CA363510975 |
327 | G>R | No |
TOPMed ClinGen |
|
|
rs1344795526 CA363510935 |
328 | P>S | No |
TOPMed ClinGen |
|
|
rs1238974156 CA363510350 |
331 | G>D | No |
gnomAD ClinGen |
|
|
rs766011184 CA3737942 |
332 | S>C | No |
ExAC gnomAD ClinGen |
|
|
CA363510307 rs1303897790 |
334 | G>A | No |
gnomAD ClinGen |
|
|
CA363510300 rs1370682651 |
335 | G>A | No |
TOPMed gnomAD ClinGen |
|
|
rs1370682651 CA363510301 |
335 | G>E | No |
TOPMed gnomAD ClinGen |
|
|
rs760066381 CA3737941 |
335 | G>R | No |
ExAC gnomAD ClinGen |
|
|
CA3737940 rs773772892 |
337 | G>E | No |
ExAC gnomAD ClinGen |
|
| TCGA novel | 337 | G>R | Variant assessed as Somatic; impact. [NCI-TCGA] | No | NCI-TCGA |
|
rs767852320 CA3737939 |
340 | T>N | No |
ExAC TOPMed gnomAD ClinGen |
|
|
rs1445275997 CA363510239 |
342 | A>V | No |
TOPMed gnomAD ClinGen |
|
|
rs1012469882 CA136913614 |
344 | A>S | No |
TOPMed gnomAD ClinGen |
|
| TCGA novel | 345 | L>M | Variant assessed as Somatic; impact. [NCI-TCGA] | No | NCI-TCGA |
|
rs149093508 CA3737936 |
346 | G>E | Variant assessed as Somatic; 0.0 impact. [NCI-TCGA] | No |
ESP ExAC gnomAD ClinGen NCI-TCGA |
|
CA363510168 rs1393030718 |
347 | I>F | No |
gnomAD ClinGen |
|
|
rs1202810284 CA363510117 |
350 | G>V | No |
gnomAD ClinGen |
|
|
rs1483927285 CA363510083 |
352 | G>E | No |
gnomAD ClinGen |
|
|
CA363510037 rs145090083 |
355 | A>P | No |
ESP ExAC TOPMed gnomAD ClinGen |
|
|
CA3737932 rs145090083 |
355 | A>T | No |
ESP ExAC TOPMed gnomAD ClinGen |
|
|
rs1438823973 CA363509997 |
357 | L>H | No |
TOPMed ClinGen |
|
|
rs758267863 CA3737929 |
358 | I>T | No |
ClinGen ExAC TOPMed gnomAD |
|
|
rs747997506 CA3737928 |
359 | G>E | No |
ExAC gnomAD ClinGen |
|
|
CA3737925 rs754772182 |
361 | I>T | No |
ExAC gnomAD ClinGen |
|
|
CA3737924 rs753577972 |
363 | W>R | No |
ExAC gnomAD ClinGen |
|
|
CA3737922 rs559420109 |
366 | R>L | No |
1000Genomes ExAC TOPMed gnomAD ClinGen |
|
|
rs559420109 CA3737921 |
366 | R>Q | No |
1000Genomes ExAC TOPMed gnomAD ClinGen |
|
|
rs529787297 CA3737923 |
366 | R>W | No |
1000Genomes ExAC gnomAD ClinGen |
|
|
CA3737920 rs768135894 |
367 | Q>P | No |
ExAC TOPMed gnomAD ClinGen |
|
|
CA3737919 rs367834402 |
368 | R>C | Variant assessed as Somatic; 0.0 impact. [NCI-TCGA] | No |
ESP ExAC TOPMed gnomAD ClinGen NCI-TCGA |
|
CA3737917 rs373730068 |
368 | R>H | No |
1000Genomes ESP ExAC TOPMed gnomAD ClinGen |
|
|
CA363509812 rs373730068 |
368 | R>L | No |
1000Genomes ESP ExAC TOPMed gnomAD ClinGen |
|
|
CA3737918 rs367834402 |
368 | R>S | No |
ESP ExAC TOPMed gnomAD ClinGen |
|
|
CA136913515 rs149968577 |
369 | R>* | No |
1000Genomes ExAC TOPMed gnomAD ClinGen |
|
|
CA3737915 rs149968577 |
369 | R>G | No |
1000Genomes ExAC TOPMed gnomAD ClinGen |
|
|
rs3176931 CA3737914 |
369 | R>Q | No |
1000Genomes ESP ExAC TOPMed gnomAD ClinGen |
|
|
CA3737913 rs759732183 |
370 | G>E | No |
ExAC gnomAD ClinGen |
|
|
CA136913514 rs546564455 CA3737912 |
371 | E>D | No |
1000Genomes ExAC TOPMed gnomAD ClinGen |
|
|
CA136913513 rs1036107113 |
373 | R>K | No |
ClinGen TOPMed gnomAD |
|
|
CA3737888 rs749159581 |
375 | A>S | No |
ClinGen ExAC TOPMed gnomAD |
|
|
CA363509678 rs1332735215 |
375 | A>V | No |
gnomAD ClinGen |
|
|
CA3737887 rs779678781 |
378 | N>K | No |
ExAC TOPMed gnomAD ClinGen |
|
|
rs745528625 CA3737885 |
384 | E>K | No |
ExAC TOPMed gnomAD ClinGen |
|
|
rs373746820 CA3737884 |
385 | R>H | No |
ESP ExAC TOPMed gnomAD ClinGen |
|
| TCGA novel | 387 | E>V | Variant assessed as Somatic; impact. [NCI-TCGA] | No | NCI-TCGA |
|
rs756762501 CA3737883 |
388 | L>R | No |
ExAC gnomAD ClinGen |
|
|
CA3737882 rs370335494 |
389 | N>H | No |
ESP ExAC gnomAD ClinGen |
|
|
COSM1077835 rs147340908 CA3737881 |
391 | S>L | endometrium [Cosmic] | No |
ESP ExAC TOPMed gnomAD ClinGen cosmic curated |
|
rs753154473 CA3737879 |
392 | E>D | No |
ExAC TOPMed gnomAD ClinGen |
|
|
CA3737877 rs745561854 |
393 | E>G | No |
ExAC TOPMed gnomAD ClinGen |
|
|
CA3737878 rs376556772 |
393 | E>K | No |
ESP ExAC TOPMed gnomAD ClinGen |
|
|
rs144228131 CA3737875 |
394 | P>A | No |
ESP ExAC TOPMed gnomAD ClinGen |
|
|
CA3737876 rs144228131 |
394 | P>S | No |
ESP ExAC TOPMed gnomAD ClinGen |
|
|
rs144228131 CA3737874 |
394 | P>T | No |
ESP ExAC TOPMed gnomAD ClinGen |
|
|
rs1373810135 CA363509194 |
397 | G>D | No |
ClinGen TOPMed |
|
|
rs200524532 CA3737872 |
397 | G>R | No |
1000Genomes ESP ExAC TOPMed gnomAD ClinGen |
|
|
CA3737871 rs762956950 |
399 | S>T | No |
ExAC gnomAD ClinGen |
|
|
CA363509101 rs1313492219 |
401 | T>N | No |
TOPMed ClinGen |
|
|
CA3737870 rs775449476 |
402 | G>E | No |
ExAC TOPMed gnomAD ClinGen |
|
|
CA363509080 rs1205664633 |
402 | G>R | No |
ClinGen TOPMed gnomAD |
|
|
rs140366801 CA3737869 |
403 | G>E | No |
ESP ExAC TOPMed gnomAD ClinGen |
|
|
CA3737867 rs776159506 |
405 | P>C | No |
ExAC TOPMed ClinGen |
No associated diseases with Q15109
10 regional properties for Q15109
| Type | Name | Position | InterPro Accession |
|---|---|---|---|
| conserved_site | Immunoglobulin/major histocompatibility complex, conserved site | 299 - 305 | IPR003006 |
| domain | Immunoglobulin subtype 2 | 29 - 106 | IPR003598-1 |
| domain | Immunoglobulin subtype 2 | 250 - 308 | IPR003598-2 |
| domain | Immunoglobulin subtype | 23 - 118 | IPR003599-1 |
| domain | Immunoglobulin subtype | 244 - 321 | IPR003599-2 |
| domain | Immunoglobulin-like domain | 31 - 116 | IPR007110-1 |
| domain | Immunoglobulin-like domain | 124 - 221 | IPR007110-2 |
| domain | Immunoglobulin-like domain | 227 - 317 | IPR007110-3 |
| domain | Immunoglobulin | 23 - 110 | IPR013151 |
| domain | CD80-like, immunoglobulin C2-set | 124 - 218 | IPR013162 |
8 GO annotations of cellular component
| Name | Definition |
|---|---|
| apical plasma membrane | The region of the plasma membrane located at the apical end of the cell. |
| cell junction | A cellular component that forms a specialized region of connection between two or more cells, or between a cell and the extracellular matrix, or between two membrane-bound components of a cell, such as flagella. |
| cell surface | The external part of the cell wall and/or plasma membrane. |
| extracellular region | The space external to the outermost structure of a cell. For cells without external protective or external encapsulating structures this refers to space outside of the plasma membrane. This term covers the host cell environment outside an intracellular parasite. |
| fibrillar center | A structure found most metazoan nucleoli, but not usually found in lower eukaryotes; surrounded by the dense fibrillar component; the zone of transcription from multiple copies of the pre-rRNA genes is in the border region between these two structures. |
| integral component of plasma membrane | The component of the plasma membrane consisting of the gene products and protein complexes having at least some part of their peptide sequence embedded in the hydrophobic region of the membrane. |
| plasma membrane | The membrane surrounding a cell that separates the cell from its external environment. It consists of a phospholipid bilayer and associated proteins. |
| postsynapse | The part of a synapse that is part of the post-synaptic cell. |
9 GO annotations of molecular function
| Name | Definition |
|---|---|
| advanced glycation end-product receptor activity | Combining with advanced glycation end-products and transmitting the signal to initiate a change in cell activity. Advanced glycation end-products (AGEs) form from a series of chemical reactions after an initial glycation event (a non-enzymatic reaction between reducing sugars and free amino groups of proteins). [GOC:signaling, PMID:12453678, PMID:12707408, PMID:7592757, PMID:9224812, Wikipedia:RAGE_(receptor)] |
| amyloid-beta binding | Binding to an amyloid-beta peptide/protein. |
| identical protein binding | Binding to an identical protein or proteins. |
| molecular adaptor activity | The binding activity of a molecule that brings together two or more molecules through a selective, non-covalent, often stoichiometric interaction, permitting those molecules to function in a coordinated way. |
| protein-containing complex binding | Binding to a macromolecular complex. |
| S100 protein binding | Binding to a S100 protein. S100 is a small calcium and zinc binding protein produced in astrocytes that is implicated in Alzheimer's disease, Down Syndrome and ALS. |
| scavenger receptor activity | Combining with any modified low-density lipoprotein (LDL) or other polyanionic ligand and delivering the ligand into the cell via endocytosis. Ligands include acetylated and oxidized LDL, Gram-positive and Gram-negative bacteria, apoptotic cells, amyloid-beta fibrils, and advanced glycation end products (AGEs). |
| signaling receptor activity | Receiving a signal and transmitting it in the cell to initiate a change in cell activity. A signal is a physical entity or change in state that is used to transfer information in order to trigger a response. |
| transmembrane signaling receptor activity | Combining with an extracellular or intracellular signal and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity or state as part of signal transduction. |
47 GO annotations of biological process
| Name | Definition |
|---|---|
| astrocyte activation | A change in morphology and behavior of an astrocyte resulting from exposure to a cytokine, chemokine, cellular ligand, or soluble factor. |
| cell surface receptor signaling pathway | The series of molecular signals initiated by activation of a receptor on the surface of a cell. The pathway begins with binding of an extracellular ligand to a cell surface receptor, or for receptors that signal in the absence of a ligand, by ligand-withdrawal or the activity of a constitutively active receptor. The pathway ends with regulation of a downstream cellular process, e.g. transcription. |
| cellular response to amyloid-beta | Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a amyloid-beta stimulus. |
| glucose mediated signaling pathway | The process in which a change in the level of mono- and disaccharide glucose trigger the expression of genes controlling metabolic and developmental processes. |
| induction of positive chemotaxis | Any process that initiates the directed movement of a motile cell or organism towards a higher concentration in a concentration gradient of a specific chemical. |
| inflammatory response | The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. |
| learning or memory | The acquisition and processing of information and/or the storage and retrieval of this information over time. |
| microglial cell activation | The change in morphology and behavior of a microglial cell resulting from exposure to a cytokine, chemokine, cellular ligand, or soluble factor. |
| negative regulation of blood circulation | Any process that stops, prevents or reduces the frequency, rate or extent of blood circulation. |
| negative regulation of interleukin-10 production | Any process that stops, prevents, or reduces the frequency, rate, or extent of interleukin-10 production. |
| negative regulation of long-term synaptic depression | Any process that stops, prevents or reduces the frequency, rate or extent of long term synaptic depression. |
| negative regulation of long-term synaptic potentiation | Any process that stops, prevents or reduces the frequency, rate or extent of long-term synaptic potentiation. |
| neuron projection development | The process whose specific outcome is the progression of a neuron projection over time, from its formation to the mature structure. A neuron projection is any process extending from a neural cell, such as axons or dendrites (collectively called neurites). |
| positive regulation of activated T cell proliferation | Any process that activates or increases the rate or extent of activated T cell proliferation. |
| positive regulation of aspartic-type endopeptidase activity involved in amyloid precursor protein catabolic process | Any process that activates or increases the frequency, rate or extent of aspartic-type endopeptidase activity involved in amyloid precursor protein catabolic process. |
| positive regulation of chemokine production | Any process that activates or increases the frequency, rate, or extent of chemokine production. |
| positive regulation of dendritic cell differentiation | Any process that activates or increases the frequency, rate or extent of dendritic cell differentiation. |
| positive regulation of endothelin production | Any process that activates or increases the frequency, rate or extent of endothelin production. |
| positive regulation of ERK1 and ERK2 cascade | Any process that activates or increases the frequency, rate or extent of signal transduction mediated by the ERK1 and ERK2 cascade. |
| positive regulation of heterotypic cell-cell adhesion | Any process that activates or increases the frequency, rate, or extent of heterotypic cell-cell adhesion. |
| positive regulation of interleukin-1 beta production | Any process that activates or increases the frequency, rate, or extent of interleukin-1 beta production. |
| positive regulation of interleukin-12 production | Any process that activates or increases the frequency, rate, or extent of interleukin-12 production. |
| positive regulation of interleukin-6 production | Any process that activates or increases the frequency, rate, or extent of interleukin-6 production. |
| positive regulation of JNK cascade | Any process that activates or increases the frequency, rate or extent of signal transduction mediated by the JNK cascade. |
| positive regulation of JUN kinase activity | Any process that activates or increases the frequency, rate or extent of JUN kinase activity. |
| positive regulation of monocyte chemotactic protein-1 production | Any process that activates or increases the frequency, rate, or extent of production of monocyte chemotactic protein-1. |
| positive regulation of monocyte extravasation | Any process that activates or increases the frequency, rate or extent of monocyte extravasation. |
| positive regulation of NF-kappaB transcription factor activity | Any process that activates or increases the frequency, rate or extent of activity of the transcription factor NF-kappaB. |
| positive regulation of NIK/NF-kappaB signaling | Any process that activates or increases the frequency, rate or extent of NIK/NF-kappaB signaling. |
| positive regulation of p38MAPK cascade | Any process that activates or increases the frequency, rate or extent of p38MAPK cascade. |
| positive regulation of protein phosphorylation | Any process that activates or increases the frequency, rate or extent of addition of phosphate groups to amino acids within a protein. |
| positive regulation of tumor necrosis factor production | Any process that activates or increases the frequency, rate or extent of tumor necrosis factor production. |
| protein localization to membrane | A process in which a protein is transported to, or maintained in, a specific location in a membrane. |
| regulation of CD4-positive, alpha-beta T cell activation | Any process that modulates the frequency, rate or extent of CD4-positive, alpha-beta T cell activation. |
| regulation of DNA binding | Any process that modulates the frequency, rate or extent of DNA binding. DNA binding is any process in which a gene product interacts selectively with DNA (deoxyribonucleic acid). |
| regulation of inflammatory response | Any process that modulates the frequency, rate or extent of the inflammatory response, the immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. |
| regulation of long-term synaptic potentiation | Any process that modulates the frequency, rate or extent of long-term synaptic potentiation. |
| regulation of NIK/NF-kappaB signaling | Any process that modulates the frequency, rate or extent of NIK/NF-kappaB signaling. |
| regulation of p38MAPK cascade | Any process that modulates the frequency, rate or extent of p38MAPK cascade. |
| regulation of spontaneous synaptic transmission | Any process that modulates the frequency, rate or extent of spontaneous synaptic transmission. |
| regulation of synaptic plasticity | A process that modulates synaptic plasticity, the ability of synapses to change as circumstances require. They may alter function, such as increasing or decreasing their sensitivity, or they may increase or decrease in actual numbers. |
| regulation of T cell mediated cytotoxicity | Any process that modulates the frequency, rate, or extent of T cell mediated cytotoxicity. |
| response to amyloid-beta | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a amyloid-beta stimulus. |
| response to hypoxia | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus indicating lowered oxygen tension. Hypoxia, defined as a decline in O2 levels below normoxic levels of 20.8 - 20.95%, results in metabolic adaptation at both the cellular and organismal level. |
| response to wounding | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus indicating damage to the organism. |
| transcytosis | The directed movement of endocytosed material through the cell and its exocytosis from the plasma membrane at the opposite side. |
| transport across blood-brain barrier | The directed movement of substances (e.g. macromolecules, small molecules, ions) through the blood-brain barrier. |
No homologous proteins in AiPD
| UniProt AC | Gene Name | Protein Name | Species | Evidence Code |
|---|---|---|---|---|
| No homologous proteins | ||||
| 10 | 20 | 30 | 40 | 50 | 60 |
| MAAGTAVGAW | VLVLSLWGAV | VGAQNITARI | GEPLVLKCKG | APKKPPQRLE | WKLNTGRTEA |
| 70 | 80 | 90 | 100 | 110 | 120 |
| WKVLSPQGGG | PWDSVARVLP | NGSLFLPAVG | IQDEGIFRCQ | AMNRNGKETK | SNYRVRVYQI |
| 130 | 140 | 150 | 160 | 170 | 180 |
| PGKPEIVDSA | SELTAGVPNK | VGTCVSEGSY | PAGTLSWHLD | GKPLVPNEKG | VSVKEQTRRH |
| 190 | 200 | 210 | 220 | 230 | 240 |
| PETGLFTLQS | ELMVTPARGG | DPRPTFSCSF | SPGLPRHRAL | RTAPIQPRVW | EPVPLEEVQL |
| 250 | 260 | 270 | 280 | 290 | 300 |
| VVEPEGGAVA | PGGTVTLTCE | VPAQPSPQIH | WMKDGVPLPL | PPSPVLILPE | IGPQDQGTYS |
| 310 | 320 | 330 | 340 | 350 | 360 |
| CVATHSSHGP | QESRAVSISI | IEPGEEGPTA | GSVGGSGLGT | LALALGILGG | LGTAALLIGV |
| 370 | 380 | 390 | 400 | ||
| ILWQRRQRRG | EERKAPENQE | EEEERAELNQ | SEEPEAGESS | TGGP |